Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 8 of 116

  1. Chemotherapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 3 small molecule completed

    1 trial

  2. Chemotherapy

    United Therapeutics Europe Ltd

    Transitional Cell Carcinoma of Ureter

    phase 3 small molecule active

    1 trial

  3. Chemotherapy

    The First People's Hospital of Lianyungang

    Endometrial Cancer

    phase 3 small molecule active

    1 trial

  4. Chemotherapy

    International Peace Maternity and Child Health Hospital

    Non Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  5. Chemotherapy + avelumab followed by avelumab + talazoparib

    Pfizer

    Ovarian Cancer

    phase 3 small molecule terminated

    1 trial

  6. Chemotherapy drug

    Chinese PLA General Hospital

    Gastric Cancer

    phase 3 small molecule active

    1 trial

  7. Chirhostim

    The George Institute

    Pancreatic cancer, Intraductal papillary mucinous intraductal neoplasia

    phase 3 small molecule active

    1 trial

  8. Cisplatin

    Children's Hospital of Fudan University

    Localized Osteosarcoma

    phase 3 small molecule completed

    1 trial

  9. Cisplatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule completed

    1 trial

  10. Cisplatin

    BRIGHT MINDS BIOSCIENCES INC.

    Squamous Cell Carcinoma of Head and Neck

    phase 3 small molecule active

    1 trial

  11. Cisplatin /ml Concentrate for Advanced head and neck cancer

    Ningbo Cancer Hospital

    Advanced head and neck cancer

    phase 3 small molecule active

    1 trial

  12. Clifutinib

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Leukemia, Acute Myeloid (AML)

    phase 3 small molecule active

    1 trial

  13. Combination Treatment of PDS0101 and Pembrolizumab

    PDS Biotechnology Corp

    Recurrent Head and Neck Cancer

    phase 3 other active

    1 trial

  14. Concurrent chemotherapy

    Disc Medicine

    Uterine Cervical Neoplasms

    phase 3 small molecule active

    1 trial

  15. Copanlisib (Aliqopa, BAY80-6946)

    Bayer HealthCare AG

    Lymphoma,Non-Hodgkin

    phase 3 small molecule completed

    1 trial

  16. Cretostimogene Grenadenorepvec

    CG Oncology

    Non Muscle Invasive Bladder Cancer

    phase 3 mab active

    2 trials

  17. Custirsen

    Teva Pharma GmbH

    Prostate Cancer

    phase 3 small molecule completed

    1 trial

  18. Cyclophosphamide

    Children's Hospital of Fudan University

    Stage III Kidney Wilms Tumor

    phase 3 small molecule active

    1 trial

  19. Cyproterone acetate

    Takeda

    Adenocarcinoma, Prostate

    phase 3 small molecule completed

    1 trial

  20. Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  21. Cytarabine

    The First People's Hospital of Lianyungang

    Leukemia

    phase 3 small molecule active

    1 trial

  22. Cytarabine

    Hoffmann-La Roche

    Leukemia, Myeloid, Acute

    phase 3 small molecule terminated

    1 trial

  23. Cytokine-Induced Killer Cells

    Sun Yat-sen University

    Carcinoma, Hepatocellular

    phase 3 mab completed

    1 trial

  24. D-US-60010-001

    Ipsen

    Metastatic Pancreatic Adenocarcinoma

    phase 3 small molecule active

    1 trial

  25. D0817C00098

    AstraZeneca AB

    BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metastatic Breast Cancer, Platinum Sensitive Relapsed Ovarian Cancer, Patients with gBRCA mutated metastatic pancreatic cancer, prostate cancer, endometrium cancer

    phase 3 small molecule active

    1 trial

  26. D081CC00006

    AstraZeneca AB

    Breast Cancer

    phase 3 small molecule active

    1 trial

  27. D20180177

    Pari Pharma GmbH

    Pancreatic adenocarcinoma (PAC)

    phase 3 small molecule active

    1 trial

  28. D3612L00005

    AstraZeneca

    HR+ / HER2- advanced breast cancer

    phase 3 small molecule active

    1 trial

  29. D3614C00001

    AstraZeneca AB

    Triple-negative Breast Cancer

    phase 3 small molecule active

    1 trial

  30. D3615C00001

    AstraZeneca AB

    Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer

    phase 3 small molecule active

    1 trial

  31. D361BC00001

    AstraZeneca AB

    Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency

    phase 3 small molecule active

    1 trial

  32. D361EC00001

    AstraZeneca AB

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  33. D4191C00140

    AstraZeneca AB

    Advanced Biliary Tract Cancers

    phase 3 small molecule active

    1 trial

  34. D419CC00002

    AstraZeneca AB

    Advanced hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  35. D419JC00001(POTOMAC)

    AstraZeneca AB

    Non-muscle invasive bladder cancer

    phase 3 small molecule active

    1 trial

  36. D5086C00001

    AstraZeneca AB

    MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma

    phase 3 small molecule active

    1 trial

  37. D5087C00001

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  38. D5160C00048

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  39. D5162C00042

    AstraZeneca AB

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  40. D5169C00001 FLAURA2

    AstraZeneca AB

    Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.

    phase 3 small molecule active

    1 trial

  41. D516FC00001(ADAURA2)

    AstraZeneca AB

    Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.

    phase 3 small molecule active

    1 trial

  42. D516KC00001

    AstraZeneca AB

    Non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  43. D516NC00001

    AstraZeneca AB

    Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  44. D533BC00001

    AstraZeneca AB

    Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  45. D6185C00001

    AstraZeneca AB

    Patients with non-small cell lung cancer (NSCLC).

    phase 3 small molecule active

    1 trial

  46. D6900C00003

    AstraZeneca AB

    B7-H4-Selected Advanced/Metastatic Endometrial Cancer.

    phase 3 small molecule active

    1 trial

  47. D7025C00001

    AstraZeneca AB

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    phase 3 small molecule active

    1 trial

  48. D7029C00001

    AstraZeneca AB

    Advanced Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.